里昂发布研报称，维持锦欣生殖(01951)“跑赢大市”评级，目标价由3.4港元上调至4.3港元。该行将锦欣生殖2024年至2025年收入及纯利预测下调5%至8%，同时将2026年收入及纯利预测上调2%。该行预料，公司去年、今年及明年收入增长分别达4%、9%及23%。

里昂指出，锦欣生殖上周五(14日)股价大幅抽升，主要是呼和浩特市推出生育补贴政策，超出市场预期。该行相信，呼和浩特市政策或短期内提振有关生育等板块，而其盈利表现仍视乎其他城市政策及如何实质地执行政策。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.